Vildagliptin – 15 years in active service with diabetologists

Pavlova M.G.

Department of Endocrinology № 1, Institute of Clinical Medicine n.a. N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

The article presents data on the vildagliptin, one of the first dipeptidyl peptidase type 4 inhibitors, which entered our clinical practice more than 15 years ago. Numerous clinical studies have proven its effectiveness in the treatment of type 2 diabetes mellitus both as monotherapy and un combination with metformin, insulin, sulfonylureas and sodium-glucose co-transporter 2 inhibitors. According to various authors, the use of vildagliptin leads to a decrease in the glycated hemoglobin level by 0.6–1.1%. In addition, body weight remains stable or decreases in most patients, which is most pronounced in combination with metformin and type 2 sodium-glucose co-transporter inhibitors.

Keywords

About the Authors

Corresponding author: Maria G. Pavlova, Cand. Sci. (Med.), Associate Professor at the Department of Endocrinology № 1, Institute of Clinical Medicine n.a. N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; pavlova_m_g@staff.sechenov.ru; ORCID: https://orcid.org/0000-0001-6073-328X 

Similar Articles